Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Contract Liability Roll-Forward: Additions / Deferrals by Year
Contract Liability Roll-Forward: Additions / Deferrals in Period ($M) ($M)
Natera Contract Liability Roll-Forward: Additions / Deferrals: $50.5M in FY2025, up 42.4% from a year earlier.
Latest, FY2025
50.5
Period ended Dec 31, 2025
Change on a year earlier
+42.4%
35.4 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (2026-02-27) ↗
Reported in Form 10-K/10-Q Note — Contract Liabilities Roll-Forward (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contract Liability Roll-Forward: Additions / Deferrals in Period ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.5 | +42.4% | Form 10-K (2026-02-27) ↗ |
| FY2024 | Dec 31, 2024 | 35.4 | -0.4% | Form 10-K (2026-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 35.6 | +22.7% | Form 10-K (2025-02-28) ↗ |
| FY2022 | Dec 31, 2022 | 29.0 | +265.9% | Form 10-K (2024-02-29) ↗ |
| FY2021 | Dec 31, 2021 | 7.92 | +230.0% | Form 10-K (2023-03-01) ↗ |
| FY2020 | Dec 31, 2020 | 2.40 | -96.3% | Form 10-K (2021-02-26) ↗ |
| FY2019 | Dec 31, 2019 | 65.0 | +49.6% | Form 10-K (2020-03-02) ↗ |
| FY2018 | Dec 31, 2018 | 43.5 | – | Form 10-K (2019-03-15) ↗ |
Cite this data
StockData. (2026). Natera Contract Liability Roll-Forward: Additions / Deferrals ($M), annual FY2018–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-additions
See every metric in the Natera KPI table. Data updated Nov 2, 2026.